Financial

Atrial Fibrillation device specialist AtriCure, Inc. has announced fourth quarter and full year 2013 financial results showing 16 percent revenue growth for the year. It also looks like the Estech acquisition is working out nicely.

Spinal implant maker ulrich medical USA, Inc., is sounding very pleased with itself as it announces another year of outstanding sales growth.

Cardio/Vascular device specialist Volcano Corporation has joined the list of companies issuing their fourth quarter and full year results for 2013. Quarterly revenue was up 6 percent on a constant currency basis, but losses increased dramatically as the company accounted for significant restructuring charges in the period.

The beancounters at DJO have invoked a $106 million write down of goodwill that has somewhat dented the numbers. Nonetheless revenue growing and income healthy, so a string set of numbers.

Endoluminal gastroesophageal reflux disease device company EndoGastric Solutions® (EGS) has reached a civil settlement with the U.S. Department of Justice over alleged misuse of procedure codes that will cost it $5.25 million.

Some outstanding sales figures from tissue sealant, hemostat, vascular and preservation services businesses underpin annual revenue growth of 7 percent.

Some solid revenue growth for Medtronic, compared with the same quarter a year ago, were somewhat spoiled by a $200 million write down following the poor outcome from its much vaunted Symplicity HTN-3 Study.

Sorin’s financials for 2013 look pretty punchy and despite a few product-lifecycle challenges appear to indicate that the financial impact of the recent earthquake experienced at one of the company’s facilities are well behind it.

Buoyed by healthy revenue growth from its Impella in-dwelling heart-assist device, Abiomed has reported a Q3 top line up 21% compared with the same period a year ago. Profits are also up with Q3 GAAP net income of $4.4 million compared to $2.7 million last year.

Johnson & Johnson has unveiled its Q4 figures which show an impressive 4.5% increase over the equivalent period a year ago. That’s not a bad return when we’re talking about $18.4 billion for one quarter. Figures include net impact of Synthes acquisition and DePuy Trauma divestiture.

Global Pharma company Shire plc, is to sell what it calls its “Dermagraft assets” to Organogenesis Inc. for what could add up to $300 million, but for now looks like a $650 million loss.

Hip fracture fixation company, X-Bolt Orthopaedics, based in Dublin, has completed an equity investment round of €1.8 million which it says will advance FDA clearance for its X-Bolt product in the US and fast track commercialisation of the product to the global export market.

Ventricular Assist Device company, HeartWare International, Inc., says it expects revenues for Q4 2013 to be approximately $53 million, bringing expected full-year 2013 revenues to approximately $208 million. This represents 87% revenue growth over prior year, signalling a strongly upward trajectory for the company.

Endovascular robot company Hansen Medical met its 2013 outlook for commercialization of systems and estimated procedures. Furthermore the company added two hospitals to its roster of Magellan Centers of Excellence in the U.S. for the training of physicians and medical staff.

Preliminary unaudited financial results that suggest 2013 sales were up 4% compared with 2012, despite US system sales declining from 620 in 2012 to 546 in 2013. It seems procedure volumes and increased system sales outside the US give reason for good cheer.

Last week we shared some pretty fiery correspondence that was made public by ConMed shareholder Voce Capital. Ten days later we see a response from ConMed, which has been filed with the SEC as part of the company’s fiduciary duty.